Mar
6

Prosecuting drug-dealing docs

A California physician has been charged with murder in the deaths of three patients who died of fatal overdoses. Dr. Hsiu-Ying “Lisa” Tseng, arrested earlier this week in Los Angeles, has been linked to five more fatal overdoses.
Tseng’s arrest comes two weeks after Dr Paul Volkman, the southern Ohio pill mill prescriber, was sentenced to four life sentences by a Cincinnati court. Volkman was convicted of killing four patients; he was associated with eight other deaths but there wasn’t enough direct evidence for convictions in those cases.
The DEA has dramatically stepped up its efforts to identify and charge physicians and pharmacists engaged in illegal distribution of controlled substances. Pill Nation II, the DEA’s latest initiative, resulted in the arrest of eight Florida physicians and two pharmacists, two Colorado docs, last fall, and a long list of other docs engaged in similar behavior.
Patients drove from as far away as Tempe Arizona to see Dr Tseng in her LA County office. Tseng had been under investigation by state and Federal agencies for years. She had been forced to give up her medical license just one day before her arrest, an event that occurred far too late for the three young men, all in their twenties, who had died after taking drugs prescribed by Tseng.
Tseng, charged with 20 counts of prescribing drugs – including oxycodone and aprazolam – for patients with no legitimate need for the drugs, had been under investigation by the DEA since 2007; her office was raided in 2010.
The sister of one of Tseng’s alleged victims had reported Tseng to the local district attorney three years ago, after her brother’s death from an overdose – two years after the DEA investigation began. I’m not pointing fingers at the FDA, rather noting how difficult it can be for law enforcement to:
– learn of the possibility that a crime has been committed
– investigate and determine if a crime has been committed (obtaining necessary judicial authorization for warrants while protecting patient confidentiality if appropriate)
– obtain a commitment from the prosecuting authorities that they support further investigation
– develop and substantiate enough information to give authorities confidence they have a solid case
– coordinate efforts with other investigating entities, develop the charges, and proceed with the arrest.
That’s likely scant comfort for the mother of Joey Rovero, but she’s turned her grief into action, forming the National Coalition Against Prescription Drug Abuse.
What does this mean for you?
If you suspect a doc or pharmacist is prescribing or dispensing illegally, contact the DEA at 1-877-RxAbuse (1-877-792-2873) – it’s confidential.


Mar
3

What health research articles can you believe?

There’s a lot of mindless blather in the media about scientific studies on health that purport to say this or that about something or other – much of it confusing, contradictory, and/or outright wrong.
While a lot is just sloppy journalism, there’s quite a bit that can be attributed to bias; physicians and/or researchers on the payroll of a specific company or industry conduct and/or report on research that is favorable to their financial supporter. Roy Poses and Gary Schwitzer have been two of the most prominent voices focused on this issue, and both have done exemplary work not only identifying individual examples of biased “research” but in calling for a higher standard of reporting by all members of the media.
Roy’s work exposing the influence of big money on academic medicine is exemplary.
That’s not to say that some of these advocates aren’t honorable and well-intentioned folks, and some of the research reports and/or advocacy positions are well-developed, legitimate and quite useful.
The tough work is identifying which ones are reliable and which may be less so. One resource is Gary’s list of experts with no links to purveyors of medical devices, medications, and/or treatment. Journalists seeking an unbiased, critical opinion can likely find someone on his list who can provide the straight scoop on the latest claim about peach pits, botox, or mercury toxicity.
A better bet may be to understand what makes for good research, and what’s not – and why, and how reporters can (unintentionally, one hopes) mischaracterize health research in such a way as to mislead the reader.
Here’s one example; a NYT article on treating baldness reported on “treating” mail hair loss by transplanting hair from the patients’ legs to their head. Schwitzer critiqued the piece as “observational with a sample of two patients, it misses nearly all of our measures and allows the author of the study to provide readers with a 777 word advertisement.” [emphasis added]
Ouch.
To answer my headline question, I’d say “yes, but check to see who the”experts” cited by the articles are and where they make their money.”


Feb
6

Employment, Economic Recovery, Workers Comp and Group Health

Friday’s news that the nation added over a quarter-million private-sector jobs in January [opens pdf] was good news indeed for health plans, workers comp insurers, service companies. But January wasn’t the only bright spot; the report indicated a lot more jobs were added last quarter than previously thought, and the unemployment rate fell by two-tenths of a point.
Since August, the unemployment rate has fallen steadily from 9.1 percent to 8.3 percent, a significant – and encouraging – improvement.
Here are a few key indicators.
– employment in architecture and engineering grew by 7000 jobs, a likely harbinger of future growth in construction and manufacturing.
– construction employment increased by 21,000 after a jump of 31,000 in December
– manufacturing jumped by a whopping 50,000 jobs, much of it in durable goods such as automobiles
– November and December employment was higher than previously reported by 60,000 jobs
So, what are the implications for health plans and work comp payers and service providers?
More workers = more health plan members. We likely won’t see much growth for another couple of months, as many employers have extended their waiting periods for eligibility. However, the steady growth in jobs at small and large employers means organic premium growth with almost no added cost-of-sale.
Occupational injury rates akafrequency will trend up for some months as new employees tend to get injured more often than their more experienced, thoroughly-trained, and knowledgeable co-workers. This means more claims for work comp insurers, and more work for the industries servicing work comp – think physical therapy, imaging, bill review and repricing, networks. Pharmacy will also tick up, but the PBMs are somewhat isolated from frequency trends by long time claimants high utilization.
Most encouraging is the overall increase in employment over the last 22 months.


Oct
20

Health inflation is down because…

We now know one of – if not the – major reasons health care cost trends have moderated – people aren’t getting care.
– Physician visits were down 8% year over year
– 77% of people delayed visits to the dentist due to cost
– a quarter didn’t get prescriptions filled due to cost.
All this didn’t happen last year, but the trends seem pretty clear.
As we noted last month, this has been good great news for health insurers, who’ve seen profits soar as medical costs for 2010 came in lower than projections, and that trend continued into this year. That said, at least one – UnitedHealth, is forecasting a return to somewhat higher utilization in the current quarter.
I’m not sure that’s going to happen.
Other than an obvious driver of utilization – fewer people with insurance means more people putting off care of all types – there’s one other factor that is almost certainly contributing to the drop off in demand for services – high deductible accounts. More accurately, accounts that don’t have any funds in them.
According to a report released in January by the Employee Benefit Research Institute, at the end of last year the average balance in HSA accounts dropped to $1355. With the number of accounts increasing about 14% from 2009 to 5.7 million, it’s not surprising that the average balance would drop as new accounts would probably have lower balances than older accounts.
But remember that these accounts are meant to fund care up to the deductible, which can range from a thousand dollars to well over five thousand dollars. If there isn’t enough money in the account to cover the deductible, people may be putting off care to save their dollars for when they really need them.


Sep
28

Health insurance premiums up, but costs aren’t. Huh?

It was all over the news yesterday and this morning- health insurance premiums are going up at near-double-digits. Front page in the NYTimes, and a top story in hundreds of other media outlets.
Premiums were up nine percent, yet health care costs (for commercial insurers) had increased less than two percent in 2010.
What gives?
The bad news was triggered by another in the never-ending series of great research from the Kaiser Family Foundation on all things health care related. This latest report contains much in the way of valuable information, but we’re going to focus on the biggie – insurance premiums increased 9 percent this year, and now top $15,000.
Premiums increased 113% over ten years; if this rate persists, and there’s no reason to think it won’t, we’re looking at family premiums above thirty thousand dollars in less than a decade.
But just a couple days ago, Mark Farrah and Associates reported commercial health plans’ medical trend rates were at a historical low.
So, how can premiums go up nine percent while underlying costs only increased two percent? How does that work? Premiums go up more than four times as fast as the cost of goods sold?
According to the piece in the NYTimes,

“Aetna and United Health/Oxford said their requested rate increases in New York largely reflected actual hospital, physician and pharmacy costs. “Our rate requests are simply keeping pace,” said Maria Gordon Shydlo, a spokeswoman for United Health Group/Oxford.”

Yet MFA’s research indicates that those costs didn’t increase anywhere near nine percent in 2010. Health plans are saying that costs will increase faster this year for myriad reasons, and therefore they have to stay in front of those increases. That may be true, and it also may well be true that health plans are looking to sock away as much cash as possible for the investments they’re making to prepare for the post-reform world.
But that’s beside the point. Which is, could your business operate this way?


Aug
15

Health plans are doing well – very well

As the economy started to recover and health reform measures began to be implemented in Q1 2011, health plans benefited with increased enrollment. According to industry analysts Mark Farrah Associates, “The Commercial sector saw a net gain of 1.6 million members between December 2010 and March 2011. In comparison, the Commercial sector gained approximately 388,000 between December 2009 and March 2010.” The increase contributed to an overall membership gain of 1.1% for the top seven health plans/insurers.
Across all seven health plans, which account for 41% of membership in the country, the news was generally positive especially on the profit side. Profits were up almost across the board, with United HealthGroup enjoying a 7.95% margin and Kaiser, Wellpoint, and Aetna all seeing net profits in excess of six percent. The good news continued in the second quarter; Kaiser saw a sixty-plus percent jump in profits in Q2; Cigna and Humana each had profit increases of more than thirty percent.
The PPACA’s requirement that health plans provide coverage for dependents up to age 26 added about 280,000 members for Wellpoint and less than 100k for Aetna over the year ended Marh 2011.
Medicare and Medicaid enrollment also saw gains; Medicaid’s increase was a bit more than commercial’s at 2.3%. In contrast, Medicaid grew by 13.6% during the recession, which economists consider ran from December 2007 to December 2009.
What does this all mean?
PPACA has already contributed to increased revenues for health plans
. Margins are solid across the board and look to be growing.
Membership is also on the upswing, driven partially by governmental programs but primarily by substantial increases on the commercial side.
Overall, it’s a good time to be in the health insurance business. That said, there’s a very, very different world coming and health plans will need all the free cash they can accumulate to prepare for health reform’s dramatic changes to their business models.


Aug
2

Get ready for big changes in provider reimbursement

Now that the debt limit deal is done, the hard stuff starts. While there’s been a lot of focus on the Pentagon budget and lack of revenue increases, the real heavy lifting will come when the super-committee convenes to figure out how to save the next $1.2 trillion. And their focus will be on Medicare, Medicaid, and provider reimbursement.

Because that’s where the ‘super-committee’ is going to have to find a big chunk of the additional savings required by the deal.
With Medicare and Medicaid accounting for a large and ever-increasing part of the deficit, by necessity the super-committee is going to have to look at provider reimbursement. As Bob Laszewski points out, they don’t have time to fundamentally alter reimbursement methodology, can’t change the eligibility parameters under the terms of the deal, and they are starting from a deficit projection that assumes the pending 29.5% cut in physician reimbursement is actually going to happen.
The 29.5% alone accounts for about $300 billion, so the super-committee has to find another $1.2 trillion on top of that $300 billion.
Where’s it going to come from?
Physician reimbursement under Medicare and Medicaid is going to get hammered.
Hospitals are going to see substantial cuts in reimbursement as well.
Pharma and PBMs participating in Part D are another big target, and one with less political pull in DC.
Insurers heavy in Medicare Advantage have been reporting nice earnings of late; that’s not going to escape the notice of deficit-cutters in Washington.
Expect to see means testing for Medicare as well.
What are the chances we see substantial cuts in reimbursement? I’d say about 100%.
Without higher revenues and given the requirements of the debt limit deal, there’s no other place to cut the hundreds of billions needed, and do so by Thanksgiving.
What does this mean for you?
Cost-shifting was a problem before this deal. It is about to become THE problem for private payers and workers comp insurers.


Jul
18

What about your five percent?

Five percent of people account for half of all medical costs.
That’s true for group health, Medicare, Medicaid, workers comp – pretty much every line of coverage.
You know that, I know that, we all know that.
But what do we DO about that?
Why do most payers use the same generic approach across all members, geographic regions, provider types, disease conditions, employers, when we all know health care is local, people are very different, surgical cases are quite different from medical ones, and non-specific back pain is NOT the same as a spinal injury.
Not surprisingly, there’s a strong correlation between obesity (and related conditions) and high cost claims. And half of the patients in the top five percent had hypertension, one-third had high cholesterol, and more than one-quarter had diabetes.
Here’s one idea. Identify patients with hypertension, hyperlipidemia, obesity (use BMI) and/or diabetes, and triage them to a clinical resource (nurse) trained in, and equipped to, address their issues. Whether you’re in the workers comp, group, or Medicare/Medicaid world, the impact of these unhealthy folks on your results will be mitigated if you pay attention right up front rather than discovering some months down the road that the ‘simple bad back’ has become a very expensive, long term, chronic pain case.


Jun
20

Consumerism in health care – no panacea, a little promise

Austin Frakt’s piece discussing the latest research findings tells us what we’ve long suspected – high deductible plans don’t seem to reduce cost trends.
Frakt highlights an analysis by Katherine Swartz of the Robert Wood Johnson Foundation, an analysis that reads in part:

the CDHP [consumer directed health plan, which uses a very high deductible] was not able to controlmedical expenditures over time and it appears that the enrollees in the CDHP spent more on hospital care than enrollees in the traditional plans…The findings from these three studies are consistent with expectations about deductibles — once the deductible has been met, there are no longer strong incentives for an enrollee to be concerned about further health care expenditures. […]
Health plans with high deductibles and uniformly applied co-payments or coinsurance rates are oftenreferred to as “blunt instruments” for reducing unnecessary health care expenditures because evidenceis mounting that people reduce both essential and nonessential care…uniformly applied cost-sharing particularly causes people to reduce their use of prescription drugs, which in turn seems to lead to use of more expensive types of care that are indicative of adverse events and poor health outcomes. [emphasis added]

Those who’ve been watching the evolution of CDHPs for some time are not surprised. In fact, we knew as long as five years ago that CDHPs = lower drug costs = more hospitalization
. There are several other problems w CDHPs – chief among them the fact that the people who spend the most dollars on health care will not alter their spending habits on iota due to a CDHP.
Here’s a discussion from a previous post.
The underpinnings of CDHPs lie in the economic theory of “Moral Hazard.” Journalist-author Malcolm Gladwell describes this as the belief that “insurance can change the behavior of the person being insured” and notes that it is popular among many economists and think-tank types and, consequently, has been influential in shaping health care delivery systems. The idea is that if insurance covers the bills, people are more likely to seek care and run up unnecessary costs.
The Moral Hazard theory falls short when confronted by the rather uncomfortable reality of actually having health care services rendered to one’s own person. Why would anyone want to subject themselves to surgery or hospitalization if there were an option to avoid it and just go fishing instead?
But on the surface, the concept makes some sense. Most people would be careful about getting an MRI if they knew they had to foot the bill, but perhaps too careful. People will not simply avoid discretionary care; they will avoid necessary care, as several studies indicate. One Rand Corporation study concludes that when individuals are required to pay more for prescription drugs, they don’t take them as they should. This leads to nasty physical and financial problems, such as more strokes, which cause lots of pain and cost lots of money to fix when a few blood-pressure pills might have sufficed. As far as drug copays go, increasing consumers’ costs actually drives up total medical expenses. It’s not a great leap to think individuals with high deductibles will likely wait before scheduling an appointment with their physician to see if a problem just goes away on its own. In a time when the Centers for Disease Control describe diabetes as “a runaway train,” is it economically wise to foster measures that discourage preventive care?
The coup de gras for CDHP is its old nemesis, the real world. CDHP’s fatal flaw is that the “consumer” part is directed at the wrong people. Half of U.S. health care costs are spent on five percent of the population. A deductible has little impact on the purchasing behavior of these folks; they’ll blow through a few thousand bucks in a couple of months
Conversely, over two-thirds of Americans spend less than a thousand dollars a year on health care. The only effect a high deductible will have on these folks is to discourage the use of preventive care.
Consumerism is not all bad – health care shouldn’t be “free” for anyone. Requiring people to share in the cost of their care should be a part of any serious reform effort. The fix for CDHP is relatively simple – get rid of high deductibles, which are unaffordable for many and may well discourage preventive care, and replace them with coinsurance per service to ensure patients have some financial skin in the game. Insurance companies should keep an income-indexed out-of pocket-maximum, while covering preventive services and maintenance medications at very low copays to encourage their use.
I”d add that employers really interested in reducing costs over the long term do have another alternative – buy a CDHP plan, and then fund the deductibles. One company has saved their clients significant dollars with this hybrid approach.


Jan
14

Guidelines – beyond the soundbite and marketing hype

Is medicine science, art, some combination of the two, or something else?
That’s not an idle question.
If you’re trying to get more scientific about how you practice medicine or what services/procedures/drugs/treatments you pay for, you are likely relying on clinical guidelines to help provide a little more perspective, hopefully one based on something other than best guess or generally accepted knowledge or tribal wisdom.
A recent study may well give you pause – the key finding is rather alarming – many guidelines are NOT based on solid research, but on work that is kindly described as rather more superficial.
Published in the Archives of Internal Medicine, the research found “More than half of the current recommendations of the IDSA (Infectious Diseases Society of America) are based on level III evidence [expert opinion] only.” [emphasis added] Note that the research focused solely on IDSA guidelines, which cover a relatively small fraction of all the guidelines in use today. Largely as a result of that conclusion, the researchers concluded “Until more data from well-designed controlled clinical trials become available, physicians should remain cautious when using current guidelines as the sole source guiding patient care decisions.”
This isn’t exactly new news. This from research on guidelines published in The Journal of the American Medical Association over a decade ago “Less than 10% of the guidelines used and described formal methods of combining scientific evidence or expert opinion. Many used informal techniques such as narrative summaries prepared by clinical experts, a type of review shown to be of low mean scientific quality and reproducibility.18​ Indeed, it was difficult to determine if some of the guidelines made any attempt to review evidence, as less than 20% specified how evidence was identified, and more than 25% did not even cite any references.”
The risk here is our sound bite-long attention span will lead some to use these studies to discount guidelines in their entirety, ignoring entirely the “Until more data from well-designed controlled clinical trials become available” recommendation.
Truth is there are lots of guidelines based on standards of evidence significantly higher than ‘expert opinion’. The pre-eminent organization in this area, and the one with the most rigorous standards, is the Cochrane Collaboration. And while not all will meet the randomized double-blind control methodology that most believe is the gold standard, many will indeed provide an ample and durable foundation on which to base medical decisions, treatment recommendations, and reimbursement.
With that said, there are organizations that trumpet their ‘guidelines’ as providing the basis for coverage and payment decisions, when a more-than-superficial examination indicates the ‘guidelines’ are built on mighty shaky ground.
The Agency for Healthcare Research and Quality maintains a database of evidence-based clinical guidelines; the listing is not comprehensive as many organizations choose to not submit their guidelines for business reasons. However, while not meeting the ‘gold’ standard described above, the standard employed by AHRQ is far superior to that of “expert opinion only”; AHRQ requirements include “Corroborating documentation can be produced and verified that a systematic literature search and review of existing scientific evidence published in peer reviewed journals was performed during the guideline development.” (while their science is solid, they really need to get some English majors involved in the whole writing thing…)
What does this mean for you?
If an organization or vendor is touting their medical criteria or guidelines, prepare – and ask – pointed questions about the methodology, development process, quality of the evidence, and staffing of the effort. The good ones will be only too happy to share their work, and the others will either not know why you aren’t impressed and/or be exposed.

A thoughtful piece on ranking the evidence used in medical guideline development can be found here. [opens pdf]
Lots more info on guidelines is available here.